Verastem, Inc. - Common Stock (NQ:VSTM)

5.560 -0.540 (-8.85%)

Streaming Delayed Price Updated: 3:24 PM EDT, Jul 31, 2026 Add to My Watchlist

Price and Volume

Volume	921,322
Open	6.040
Bid (Size)	5.550 (1,100)
Ask (Size)	5.560 (1,800)
Prev. Close	6.100
Today's Range	5.550 - 6.090
52wk Range	3.430 - 11.24
Shares Outstanding	77,740,000
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

July 28, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

July 23, 2026

From Verastem Oncology

Via Business Wire

Performance

YTD	-23.1%	-23.1%
1 Month	+45.5%	+45.5%
3 Month	+1.8%	+1.8%
6 Month	-13.3%	-13.3%
1 Year	-10.8%	-10.8%

More News

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

July 22, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2026

From Verastem Oncology

Via Business Wire

Verastem Inc (NASDAQ:VSTM) Mixed Q1 Results Disappoint on Revenue Miss ↗

May 07, 2026

Via Chartmill

VS-7375 Demonstrates Clinical Activity with a Favorable Safety and Tolerability Profile in TARGET-D 101 Phase 1/2 Clinical Trial in Patients with Advanced KRAS G12D-Mutated Solid Tumors

June 23, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

June 17, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer

June 16, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program

June 15, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

June 03, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at Jefferies Healthcare Conference

May 27, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Appoints Michael P. Bailey to its Board of Directors

May 26, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology to Present at Upcoming Investor Conferences

May 12, 2026

From Verastem Oncology

Via Business Wire

Verastem Q1 Earnings Call Highlights ↗

May 09, 2026

Via MarketBeat

Verastem (VSTM) Q1 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer

May 08, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

May 07, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer

April 30, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026

April 23, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers

April 10, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 02, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026

March 17, 2026

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers

March 17, 2026

From Verastem Oncology

Via Business Wire

Verastem (VSTM) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? ↗

March 04, 2026

Via Stocktwits

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?

Yes, Verastem, Inc. - Common Stock is publicly traded.

What exchange does Verastem, Inc. - Common Stock trade on?

Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Verastem, Inc. - Common Stock?

The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market

What is the current price of Verastem, Inc. - Common Stock?

The current price of Verastem, Inc. - Common Stock is 5.560

When was Verastem, Inc. - Common Stock last traded?

The last trade of Verastem, Inc. - Common Stock was at 07/31/26 03:24 PM ET

What is the market capitalization of Verastem, Inc. - Common Stock?

The market capitalization of Verastem, Inc. - Common Stock is 432.23M

How many shares of Verastem, Inc. - Common Stock are outstanding?

Verastem, Inc. - Common Stock has 432M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.